Why Shares of Axsome Therapeutics Slumped Today
From Yahoo Finance: 2025-04-01 13:23:00
Shares of Axsome Therapeutics (NASDAQ: AXSM) fell 6% following disappointing results from a phase 3 trial of solriamfetol for major depressive disorder. The trial showed no statistical improvement in the overall population. However, positive responses were seen in MDD patients with severe excessive daytime sleepiness (EDS).
The company plans a phase 3 trial for MDD patients with EDS in 2025. While the mixed trial results impacted the stock, success in severe EDS cases could lead to approval. However, approval only for severe EDS would result in lower sales compared to approval for the total EDS population.
Consider the Motley Fool’s top 10 stock picks, which exclude Axsome Therapeutics. Their past recommendations have led to significant returns, with Nvidia being a prime example. Don’t miss out on potential gains by joining the Stock Advisor program for access to the latest top picks.